TriSalus Life Sciences (NASDAQ:TLSI) Director Gary Gordon Buys 10,000 Shares of Stock

TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Director Gary Gordon purchased 10,000 shares of the firm’s stock in a transaction on Friday, May 15th. The stock was bought at an average price of $2.46 per share, for a total transaction of $24,600.00. Following the purchase, the director owned 72,510 shares in the company, valued at approximately $178,374.60. This represents a 16.00% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

TriSalus Life Sciences Stock Up 13.1%

Shares of TLSI stock opened at $3.03 on Tuesday. The stock has a market cap of $185.76 million, a P/E ratio of -2.15 and a beta of 0.56. TriSalus Life Sciences, Inc. has a 52 week low of $2.20 and a 52 week high of $7.95. The company has a quick ratio of 5.46, a current ratio of 5.78 and a debt-to-equity ratio of 2.58. The company’s fifty day simple moving average is $4.14 and its two-hundred day simple moving average is $5.11.

TriSalus Life Sciences (NASDAQ:TLSI) last announced its quarterly earnings results on Thursday, March 5th. The company reported ($0.12) EPS for the quarter, topping the consensus estimate of ($0.13) by $0.01. The company had revenue of $13.21 million during the quarter, compared to analysts’ expectations of $13.20 million. Analysts predict that TriSalus Life Sciences, Inc. will post -0.45 EPS for the current fiscal year.

Analyst Ratings Changes

Several analysts have recently issued reports on TLSI shares. Wall Street Zen upgraded shares of TriSalus Life Sciences from a “sell” rating to a “hold” rating in a research report on Saturday, March 7th. Weiss Ratings cut shares of TriSalus Life Sciences from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday, May 13th. Lake Street Capital decreased their target price on shares of TriSalus Life Sciences from $10.00 to $8.00 and set a “buy” rating on the stock in a research report on Wednesday, May 13th. Finally, Canaccord Genuity Group decreased their target price on shares of TriSalus Life Sciences from $12.00 to $7.00 and set a “buy” rating on the stock in a research report on Friday, March 6th. Two analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $7.50.

Institutional Trading of TriSalus Life Sciences

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in TLSI. First Light Asset Management LLC bought a new position in TriSalus Life Sciences in the 1st quarter worth about $20,267,000. Nantahala Capital Management LLC grew its stake in TriSalus Life Sciences by 1.5% in the 4th quarter. Nantahala Capital Management LLC now owns 2,070,827 shares of the company’s stock worth $14,454,000 after acquiring an additional 30,582 shares in the last quarter. Wasatch Advisors LP bought a new position in TriSalus Life Sciences in the 1st quarter worth about $5,752,000. Vanguard Group Inc. grew its stake in TriSalus Life Sciences by 42.4% in the 3rd quarter. Vanguard Group Inc. now owns 1,159,575 shares of the company’s stock worth $5,392,000 after acquiring an additional 345,186 shares in the last quarter. Finally, Gilder Gagnon Howe & Co. LLC grew its stake in TriSalus Life Sciences by 32.1% in the 2nd quarter. Gilder Gagnon Howe & Co. LLC now owns 1,092,975 shares of the company’s stock worth $5,957,000 after acquiring an additional 265,618 shares in the last quarter. 2.58% of the stock is owned by hedge funds and other institutional investors.

About TriSalus Life Sciences

TriSalus Life Sciences, Inc is a clinical-stage biotechnology company focused on the development and commercialization of non-invasive drug–device combination therapies for oncology applications. Leveraging proprietary electroporation and ultrasound platforms, the company aims to enhance the localized delivery and efficacy of established chemotherapeutic agents while reducing systemic toxicity. Its lead programs target hard-to-treat head and neck cancers, where improved tumor control and patient tolerability remain significant unmet needs.

The company’s pipeline comprises investigational product candidates in early and mid-stage clinical trials, including studies that combine its electrochemotherapy platform with radiation therapy and immuno-oncology agents.